This course has expired. View available courses.
English
The role of the novel oral anticoagulants (NOACs). What the GP needs to know. – QI&CPD – Category 1
DURATION
PROFESSION
Physician
# OF CREDITS
40
ACCREDITATION
EXPIRY DATE
2017-10-17
Learning objectives
After completing this module, GPs will be better able to:
- Describe the role anticoagulation plays in stroke prevention in non-valvular atrial fibrillation (NVAF) and at least one additional risk factor for stroke, and in the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE))
- Discuss the indications for anticoagulation therapy in patients with NVAF and at least one additional risk factor for stroke, and in VTE
- Evaluate safety factors associated with initiation of anticoagulants, such as stroke risk in patients with NVAF and at least one additional risk factor for stroke and the risk of bleeding
- Review the evidence regarding novel oral anticoagulant treatment options for patients with NVAF and at least one additional risk factor for stroke and patients with VTE
- Determine how to most effectively initiate and manage the novel oral anticoagulants (NOACs) for the:
- prevention of stroke in patients with NVAF and at least one additional risk factor for stroke
- management of DVT, (and PE if applicable), in general practice